1
|
Martino SD, Petri GL, De Rosa M. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn? J Med Chem 2024; 67:885-921. [PMID: 38179950 DOI: 10.1021/acs.jmedchem.3c01971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]
Abstract
Hepatitis C viral (HCV) infection is the leading cause of liver failure and still represents a global health burden. Over the past decade, great advancements made HCV curable, and sustained viral remission significantly improved to more than 98%. Historical treatment with pegylated interferon alpha and ribavirin has been displaced by combinations of direct-acting antivirals. These regimens include drugs targeting different stages of the HCV life cycle. However, the emergence of viral resistance remains a big concern. The design of peptidomimetic inhibitors (PIs) able to fit and fill the conserved substrate envelope region within the active site helped avoid contact with the vulnerable sites of the most common resistance-associated substitutions Arg155, Ala156, and Asp168. Herein, we give an overview of HCV NS3 PIs discovered during the past decade, and we deeply discuss the rationale behind the structural optimization efforts essential to achieve pangenotypic activity.
Collapse
Affiliation(s)
- Simona Di Martino
- Drug Discovery Unit, Medicinal Chemistry Group, Ri.MED Foundation, Palermo 90133, Italy
| | - Giovanna Li Petri
- Drug Discovery Unit, Medicinal Chemistry Group, Ri.MED Foundation, Palermo 90133, Italy
| | - Maria De Rosa
- Drug Discovery Unit, Medicinal Chemistry Group, Ri.MED Foundation, Palermo 90133, Italy
| |
Collapse
|
2
|
Hamdi A, Laurent MY, Hémon-Ribaud A, Mostafa AS, Massoud MA, Selim KB, Dujardin G. 1,3-Dipolar cycloaddition of vinyloxy quinolines with α-alkoxy carbonyl aldonitrones or cyclic surrogates: A comparative study for an asymmetric access to trans 4-quinolinoxy oxaprolines. Tetrahedron 2019. [DOI: 10.1016/j.tet.2018.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
Jin S, Niu Y, Liu C, Zhu L, Li Y, Cui S, Xiong Z, Cheng M, Lin B, Liu Y. Gold(I)-Initiated Cycloisomerization/Diels–Alder/Retro-Diels–Alder Cascade Strategy to Biaryls. J Org Chem 2017; 82:9066-9074. [DOI: 10.1021/acs.joc.7b01561] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Shengfei Jin
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Yujie Niu
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Wuya
College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Chengjun Liu
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Wuya
College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Lifeng Zhu
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Wuya
College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Yangming Li
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Wuya
College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Shanshan Cui
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Zhiling Xiong
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Maosheng Cheng
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Bin Lin
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| | - Yongxiang Liu
- Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Wuya
College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China
- Institute of Drug Research in Medicine Capital of China, Benxi 117000, P. R. China
| |
Collapse
|